Minervax ApS

Venture capital mega-rounds of $100m or more – like the $245m series A round that Aiolos Bio Inc. announced on 24 October – have played a big part in surging quarterly and annual totals of biopharma

It is too soon for the Pitchbook and National Venture Capital Association (NVCA) Venture Monitor report detailing fourth quarter 2022 VC investment, including a breakdown of biopharmaceutical fundra

Minervax ApS has added to its cash pile as it heads into pivotal trials in a two-horse race with Pfizer Inc. to bring an effective vaccine against Group B streptococcus (GBS) to the market. The Dan

DTX401, a one-time gene therapy for glycogen storage disease type Ia (GSDIa), and GBS-NN/NN2, a maternal vaccine for preventing group B streptococcal infection in newborns, are the latest investigatio